Dow Jones closes flat after oil rebound and doubts in Gilead tests

Dow Jones closes flat after oil rebound and doubts in Gilead tests

In a wild session last April 23, the Dow Jones closed 39.44 points despite rallying 400 points within the day.

Earlier this week, oil went into an emotional roller coaster as its May futures contract went as low as negative, resulting in oil prices to drop significantly.

Aside from oil, the Dow Jones also had a roller-coaster trading session as mixed sentiments from different analysts because of the jobless claims reports as well as the updated drug trial from remdesivir.

Dow Jones closes flat after oil rebound and doubts in Gilead tests

Charles Dumas, chief economist at TS Lombard writes:

“The resulting price action is highly damaging for many oil producers, and certainly implies a sharp fallback in US shale fracking, contributing to much weaker US exports and capex later this year.”

West Texas Intermediate (WTI) futures for June delivery are holding at above US $17 [AU $27] per barrel as traders increased bets on U.S. production cuts after bouncing from lows at around $6 to $7 mid-week.

Dow Jones closes flat after oil rebound and doubts in Gilead tests

Oil prices also went sharply year to date despite their strong rally the past two days.

Oil rebound euphoria blocked

Oil’s volatility helped equities recover back some of their steep losses earlier in the week. Both the S&P 500 and Dow dropped more than four percent this week before rallying around two percent last April 22.

However, oil’s rebound was not enough for Dow Jones to push its rally as the recent U.S. jobless claims report over 4.4 million, totaling to 26 million for the past five weeks.

The five-week total has also surpassed all of the job gains since the Great Recession.

Dow Jones closes flat after oil rebound and doubts in Gilead tests

Gilead confidence low after drug trial results

Last week, Gilead had leaked reports about their clinical drug trial for remdesivir showing “promising results.”

However due to “low enrollment,” the study was terminated as the results are inconclusive. Equities tried to bounce on the back of Gilead’s statement before closing along the Dow Jones flatline but Gilead Sciences shares closed 4.3% lower.

Jim Cramer, the host of CNBC’s Mad Money, is still hopeful that remdesivir might help in combating COVID-19 as he said in a tweet:

A Chinese drug trial reported by STAT News also shows the ineffectiveness of remdesivir. The summary of the study results was also inadvertently posted by the World Health Organization (WHO) on April 23, but immediately got taken down.

WHO has been receiving criticisms lately on its measures on handling the coronavirus especially with its mutual connections with China.

Images courtesy of geralt/Pixabay, The Trading Comedy/TradingView

Micky is a news site and does not provide trading, investing, or other financial advice. By using this website, you affirm that you have read and agree to abide by our Terms and Conditions.
Micky readers - you can get a 10% discount on trading fees on FTX and Binance when you sign up using the links above.